 correl respons surviv patient multipl myeloma vincristin melphalan cyclophosphamid prednison vincristin melphalan cyclophosphamid prednison vmcp multi-drug regimen untreat patient multipl myeloma MM symptomat duri stage II iii refractori prognost signific variou pretreat characterist term therapeut respons southwest oncolog group swog chronic leukemia-myeloma task forc TF criteria surviv therapeut respons swog TF patient signific invers correl myeloma cell mass serum calcium bone statu median surviv time stage II stage iii patient month serum microglobulin equal micrograms/ml variabl surviv durat multi-vari analysi risk therapeut respons time-depend variabl effect surviv data correl respons surviv inadequ respons assess criteria treatment cur current therapeut approach death complic